Reply #23: Sure. It's not unlike reading all the cautionaries and lengthy

[chill_wind]

litanies of possible side effects or adverse effects of pharmaceutical listings in the PDR -- or even the patient literature stapled to your prescription. I think most of us get it about the need and practice of overstating, erring on the side of caution and also limiting legal exposure, etc.

What's really important is that, while some of it is still being kept proprietary trade secret, we now have more public information in the time since the MSDS was released just less than 48 hrs ago, and that much, at least, has served as a jumping off point for more scientific and policy scrutiny. Enough question has emerged in short time, it seems, that now we're reading that FWIW, BP has said it has halted the treatment for further testing for safety.

My point in posting the OP was to disseminate information that we didn't have the day before.
Let's have more information- not suppression of it- and let it sort out however it will.
That's my view.